Latest Boehringer Ingelheim Corporation Stories
Boehringer Ingelheim launches comprehensive support resources for people with idiopathic pulmonary fibrosis RIDGEFIELD, Conn., Oct.
Company to make OFEV available to IPF community within 10 days, along with comprehensive patient support resources RIDGEFIELD, Conn., Oct.
RIDGEFIELD, Conn., Oct.
- LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing
RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S.
Approval Marks New Inhaler Choice for tiotropium RIDGEFIELD, Conn., Sept. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S.
- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany,
RIDGEFIELD, Conn., Sept.
For U.S. Media Only RIDGEFIELD, Conn., Sept.
Additionally, data from the WISDOM trial on stepwise withdrawal of ICS in COPD was also presented at ERS and simultaneously published in the New England Journal of Medicine RIDGEFIELD,